At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...

Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...

The bills would require insurers to cover germline multi-gene testing for inherited cancer risk and imaging with no out-of-pocket cost for patients.

Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.

NEW YORK – Neok Bio on Thursday said it has been cleared by the US Food and Drug Administration to begin a Phase I trial of its bispecific antibody-drug conjugate (ADC) NEOK001 in solid tumors.

NEW YORK – Ocugen said on Friday that it has raised about $22.5 million in a recent public offering.

The partners will use 4D Path's imaging-based Q-Plasia OncoReader in a Phase II trial testing doublet and triplet regimens comprising Trodelvy, Padcev, and Keytruda.

NEW YORK – Bristol Myers Squibb and Janux Therapeutics on Thursday announced they will jointly develop an undisclosed tumor-activated therapeutic targeting a validated solid tumor antigen expressed ...

NEW YORK – Boston Children's Hospital has granted a worldwide license for an investigational gene therapy for sickle cell disease and beta thalassemia to Caring Cross, the nonprofit announced this ...

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...